(Press-News.org) CHICAGO --- HIV has a voracious sweet tooth, which turns out to be its Achilles' heel, reports a new study from Northwestern Medicine and Vanderbilt University.
After the virus invades an activated immune cell, it craves sugar and nutrients from the cell to replicate and fuel its wild growth throughout the body.
Scientists discovered the switch that turns on the immune cell's abundant sugar and nutrient pipeline. Then they blocked the switch with an experimental compound, shutting down the pipeline, and, thereby, starving HIV to death. The virus was unable to replicate in human cells in vitro.
The discovery may have applications in treating cancer, which also has an immense appetite for sugar and other nutrients in the cell, which it needs to grow and spread.
The study will be published May 28 in PLOS Pathogens.
"This compound can be the precursor for something that can be used in the future as part of a cocktail to treat HIV that improves on the effective medicines we have today," said corresponding study author, Harry Taylor, research assistant professor in medicine at Northwestern University Feinberg School of Medicine.
"It's essential to find new ways to block HIV growth, because the virus is constantly mutating," said Taylor, also a scientist at Northwestern Medicine's HIV Translational Research Center. "A drug targeting HIV that works today may be less effective a few years down the road, because HIV can mutate itself to evade the drug."
HIV needs to grow in a type of immune cell (CD4+ T cell) that is active, meaning it is already responding to pathogens in the blood. Activation increases the T cell's supplies of sugar and other critical nutrients needed for both cell and virus growth.
Until now, no one knew the first step that signaled a newly activated T cell to stock up on sugar and other nutrients. Those nutrients become the building blocks of genetic material the cell and the virus need to grow.
Northwestern and Vanderbilt scientists figured out that first step in stocking the T cell's pantry involved turning on a cell component called phospholipase D1 (PLD1). Then they used an experimental compound to block PLD1 and shut down the pipeline.
This is believed to be the first time scientists have targeted the virus's ability to pilfer the cell's pantry to stop its growth. A related approach was attempted in the 1990s but the drugs used sometimes killed healthy cells and had serious side effects in HIV patients.
The Northwestern team's new approach is a gentler, non-toxic way to block HIV access to the cell's "pantry."
New strategy could reduce organ damage
The approach has additional benefits beyond the initial goal of preventing HIV from reproducing.
The compound also slowed the proliferation of the abnormally activated immune cells, the study found. Current HIV medications stop HIV growth but do not affect the abnormal excess activation and growth of immune cells triggered by HIV.
The excess immune cell growth is believed to contribute to the life-long persistence of HIV and leads to excess inflammation that causes premature organ damage in HIV patients -- even when the virus is suppressed by current medicines.
"Perhaps this new approach, which slows the growth of the immune cells, could reduce the dangerous inflammation and thwart the life-long persistence of HIV," Taylor said.
HIV's hunt for sugar and world domination
When HIV enters the bloodstream, it searches out active CD4+ T cells, the commanders-in-chief of the immune system. These active cells are already responding to other pathogens or allergens in the blood and are guzzling glucose and amino acids from the blood, which they need to churn out the building blocks of DNA. The cells' factories are at full throttle, making these building blocks to produce an army of soldiers to fight that cold that has just started to give you a sore throat or the chills.
When HIV finds an active CD4+ T cell, it hijacks the cell's glucose supply and factory to build millions of copies of itself and invade other cells.
"It's a monster that invades the cell and says 'feed me!' " Taylor said. "It usurps the entire production line."
Cancer cells crave sugar, too
The idea to test this compound for HIV evolved from Taylor's relationship with chemists at Vanderbilt University, where he was on faculty before he joined Northwestern in 2012.
Taylor knew his Vanderbilt colleagues had identified a compound in their massive screening for potential drugs that block the growth of breast cancer cells. The compound stopped breast cancer cells from spreading by blocking PLD1. Taylor and his Vanderbilt colleagues wondered if blocking this same enzyme in the CD4+ T cell would cut off HIV's use of the cell's nutrient supply and slow the invading HIV.
That's exactly what their study shows. In vitro, the compound shut off the glucose and other nutrients and prevented HIV from having enough building blocks of DNA to make the genetic material it needed to reproduce.
Now, Taylor wants to identify even more compounds for development into future medicines that will limit re-stocking of the cell's pantry to starve HIV -- without harming cells.
"This discovery opens new avenues for further research to solve today's persisting problems in treating HIV infection: avoiding virus resistance to medicines, decreasing the inflammation that leads to premature aging, and maybe even one day being able to cure HIV infection," said Dr. Richard D'Aquila, director of Northwestern's HIV Translational Research Center. He also is the Howard Taylor Ricketts Professor of Medicine at Feinberg and a physician at Northwestern Memorial Hospital.
INFORMATION:
Key Vanderbilt collaborators are Craig W. Lindsley and H. Alex Brown.
This research was supported in part by Northwestern Medicine's HIV Translational Research Center, the National Institute of Mental Health grant U54-MH084659, National Institute of Diabetes and Digestive and Kidney Diseases grant 5R21DK094735, the National Center for Research Resources grant 5KL2RR024977 and the National Cancer Institute grant CA060553, of the National Institutes of Health.
Zoonotic malaria has been shown to be caused by two genetically distinct Plasmodium knowlesi parasite subpopulations associated with different monkey host species in Malaysia, according to new research published in PLOS Pathogens. The authors believe this could have important implications for how the parasite adapts and spreads in humans.
Plasmodium knowlesi is a zoonotic malaria parasite which is common in forest-dwelling macaques. In recent years, increasing numbers of cases of knowlesi malaria have been reported in humans. The disease is now the most common form of ...
Different people can vary substantially in their genetic susceptibility to viruses, including HIV. Although the biology that underlies this variation in humans is still being uncovered, it seems that we may be able to learn some key lessons from our closest cousins. A gene variant in chimpanzees in a Tanzanian wildlife preserve probably protects them from rapidly succumbing to the primate equivalent of HIV, Stanford University School of Medicine scientists report in the open access journal PLOS Biology, publishing May 28.
The wild chimps inhabit Gombe Stream National ...
EVANSTON, Ill. --- Can we learn to rid ourselves of our implicit biases regarding race and gender? A new Northwestern University study indicates that sleep may hold an important key to success in such efforts.
Building on prior research, the Northwestern investigators aimed to find out whether learning to alter habitual reactions to other people could be enhanced during sleep.
Other researchers have documented many unsavory consequences of common social biases. When playing a videogame with instructions to shoot only people carrying weapons, players were more likely ...
CORVALLIS, Ore. - A new study shows how huge influxes of fresh water into the North Atlantic Ocean from icebergs calving off North America during the last ice age had an unexpected effect - they increased the production of methane in the tropical wetlands.
Usually increases in methane levels are linked to warming in the Northern Hemisphere, but scientists who are publishing their findings this week in the journal Science have identified rapid increases in methane during particularly cold intervals.
These findings are important, researchers say, because they identify ...
TAMPA, Fla. - Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer. Scott J. Antonia, M.D., Ph.D., chair of the Thoracic Oncology Department at Moffitt Cancer Center will be presenting data from a phase 1b dose-escalation and expansion study of MEDI4736 combined with tremelimumab at the 2015 American Society of Clinical Oncology ...
TAMPA, Fla. - Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer. A team of researchers led by Nagi B. Kumar, Ph.D., R.D., F.A.D.A. at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men ...
TAMPA, Fla. - Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. Preclinical studies suggest that JAK2 inhibitors may be an effective treatment option for CMML. Eric Padron, M.D., assistant member of the Malignant Hematology Program at Moffitt Cancer Center will report on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients ...
TAMPA, Fla. - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
Nivolumab targets a protein called the programmed death-1 (PD-1) receptor. The ...
Many living things can respond to electric fields, either moving or using them to detect prey or enemies. Weak electric fields may be important growth and development, and in wound healing: it's known that one of the signals that guides cells into a wound to repair it is a disturbance in the normal electric field between tissues. This ability to move in response to an electric field is called galvanotaxis or electrotaxis.
UC Davis dermatology professor Min Zhao, Peter Devroetes at Johns Hopkins University and colleagues hope to unravel how these responses work, studying ...
Unstable funding is threatening the viability of academic biomedical research in this country, according to a new paper published this week in the journal Science Translational Medicine. The paper was written jointly by the deans of 19 prominent medical schools around the country. Among this group is University of Maryland School of Medicine Dean E. Albert Reece.
"We must reinvigorate the federal-academic partnership for research across all sciences," the authors write. If the current trends in funding continue, both established investigators and early-career scientists ...
